As of 2012, 29 million people in the United States suffered from diabetes mellitus.1 Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are a new class of antihyperglycemic agents used as adjunctive therapy to standard treatment regimens. The gene discussed is SLC5A2; the disease is diabetes mellitus.